2017医药及生命科学趋势（英文版）_14页_854kb

2017 Pharmaceuticals and Life Sciences Industry Trends Summary

Core Content

The 2017 Pharmaceuticals and Life Sciences Industry Trends report highlights the transformation of the healthcare industry, often referred to as the New Health Economy, and its implications for pharmaceutical companies. This shift is driven by a combination of factors including healthcare system reforms, technological advancements, and changing patient expectations.

Main Points

1. The New Health Economy

• Shift from Volume to Value: The healthcare system is moving towards a value-based model, where payment is based on outcomes rather than the volume of services provided.
• Consumer-Facing Industry: Pharma companies must become more proactive in engaging with patients and focus on delivering health outcomes, well-being, and optimal illness management.
• Patient Engagement: A "patient first" approach is essential, moving away from traditional top-down promotion to a more flexible, interactive model that provides patients with better tools and information.

2. The Rise of Analytics

• Data Analytics Integration: Pharma companies are increasingly using enterprise analytics and advanced data science to inform business decisions across the value chain.
• Data Utilization: The industry is leveraging large, diverse data sets from electronic medical records, high-resolution imaging, and genomics to enhance decision-making.
• Strategic Use of Data: Companies must avoid the "myth of big data" and instead focus on strategic insights that address specific business questions, using relevant data and appropriate analytical methods.
• Benefits of Analytics: Analytics can help optimize clinical trials, inform commercial strategies, manage risk and compliance, and enhance supply chain operations.

3. The Value Equation Tipping Point

• Value Assessment: Pharma companies face increasing pressure to demonstrate the value of their drugs to payors, regulators, and patients.
• Stakeholder Groups: The value of a drug must be communicated to four key groups: funders (payors), assessors (third-party evaluators), executors (healthcare providers), and patients.
• Real-World Evidence: Companies are using real-world data and collaborative studies to build a compelling value narrative.
• Pay for Performance Models: These models, where payment is tied to outcomes, are becoming more prevalent and are expected to shape future reimbursement strategies.

Key Information

• Talent Constraints: There is a significant shortage of big data and analytics talent, with demand expected to outpace supply by 50–60% by 2018.
• Technological Tools: Pharma companies are using digital tools such as mobile apps, biosensors, and online portals to engage with patients and monitor treatment outcomes.
• Behavioral Insights: Companies are exploring behavioral sciences to improve patient compliance and self-care, using incentives and social influence.
• Patient Activation: Understanding and addressing patient activation levels (knowledge, skills, willingness to manage health) is crucial for improving engagement and compliance.
• Regulatory and Commercial Success: Patient engagement efforts are linked to regulatory and commercial success, as decisions about drug approval and marketing are increasingly based on patient outcomes.

Conclusion

The report emphasizes that the pharmaceutical industry must adapt to the evolving healthcare landscape by embracing data analytics, focusing on patient-centric strategies, and redefining the value of their products. These changes are not only necessary for survival but also for shaping the future of patient care and healthcare delivery.